Item 4 of the Statement is hereby amended and supplemented as follows: On May 21, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Sanofi, a French societe anonyme ("Parent" or "Sanofi"), and Vesper Acquisition Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which, Merger Sub would merge with and into the Issuer (the "Merger"), with the Issuer surviving the merger as a wholly-owned subsidiary of Parent. On August 4, 2025, at a special meeting of stockholders of the Issuer, the Issuer's stockholders voted to adopt the Merger Agreement. On August 5, 2025, the Merger closed and each share of the Issuer's Common Stock issued and outstanding, including all of the shares of Common Stock owned by the Reporting Persons, was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest plus (ii) one contingent value right, representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone.